Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objectives: Mosaic gain of chromosome 1q (chr1q) has been associated with malformation of cortical development (MCD) and epilepsy. Hyaline protoplasmic astrocytopathy (HPA) is a rare neuropathologic finding seen in cases of epilepsy with MCD. The cell-type specificity of mosaic chr1q gain in the brain and the molecular signatures of HPA are unknown.

Methods: We present the case of a child with pharmacoresistant epilepsy who underwent epileptic focus resections at age 3 and 5 years and was found to have mosaic chr1q gain and HPA. We performed single-nuclei RNA sequencing (snRNA-seq) of brain tissue from the second resection.

Results: snRNA-seq showed increased expression of chr1q genes specifically in subsets of neurons and astrocytes. Differentially expressed genes associated with inferred chr1q gain included and genes associated with cell adhesion or migration. A subpopulation of astrocytes demonstrated marked enrichment for synapse-associated transcripts, possibly linked to the astrocytic inclusions observed in HPA.

Discussion: snRNA-seq may be used to infer the cell-type specificity of mosaic chromosomal copy number changes and identify associated gene expression alterations, which in the case of chr1q gain may involve aberrations in cell migration. Future studies using spatial profiling could yield further insights on the molecular signatures of HPA.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10997208PMC
http://dx.doi.org/10.1212/NXG.0000000000200142DOI Listing

Publication Analysis

Top Keywords

chr1q gain
16
cell-type specificity
12
specificity mosaic
12
epilepsy hyaline
8
hyaline protoplasmic
8
protoplasmic astrocytopathy
8
mosaic chr1q
8
molecular signatures
8
signatures hpa
8
genes associated
8

Similar Publications

Cell-Type Specificity of Mosaic Chromosome 1q Gain Resolved by snRNA-seq in a Case of Epilepsy With Hyaline Protoplasmic Astrocytopathy.

Neurol Genet

April 2024

From the Medical Scientist Training Program (K.L., E.W.T.); Department of Pathology (C.R.C., W.P.D., T.T., S.K.); Department of Neurological Surgery (C.R.C.); Weill Institute for Neuroscience (C.R.C., M.F.P.); Department of Laboratory Medicine (Z.Q., A.P.W., E.W.T.); Division of Epilepsy (N.S.S., M.

Objectives: Mosaic gain of chromosome 1q (chr1q) has been associated with malformation of cortical development (MCD) and epilepsy. Hyaline protoplasmic astrocytopathy (HPA) is a rare neuropathologic finding seen in cases of epilepsy with MCD. The cell-type specificity of mosaic chr1q gain in the brain and the molecular signatures of HPA are unknown.

View Article and Find Full Text PDF

Introduction: Mosaic gain of chromosome 1q (chr1q) has been associated with malformation of cortical development (MCD) and epilepsy. Hyaline protoplasmic astrocytopathy (HPA) is a rare neuropathological finding seen in cases of epilepsy with MCD. The cell-type specificity of mosaic chr1q gain in the brain and the molecular signatures of HPA are unknown.

View Article and Find Full Text PDF
Article Synopsis
  • - The study highlights the challenge in creating targeted therapies for Multiple Myeloma (MM) due to the rarity of genetic abnormalities, with the common amplification of chromosome 1q (Amp1q) linked to poorer outcomes for patients.
  • - Researchers used large-scale screening methods to identify that MM patients with Amp1q have increased sensitivity to a combination of MCL1 and PI3K inhibitors, which could potentially lead to more effective treatments.
  • - Further analysis through single-cell RNA sequencing revealed differences in the PI3K pathway's activity between cancer cells with and without Amp1q, suggesting that targeting this pathway along with MCL1 could enhance treatment efficacy for affected patients.
View Article and Find Full Text PDF

Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer that occurs predominantly in patients with previous liver conditions. In the absence of an ideal screening modality, HCC is usually diagnosed at an advanced stage. Recent studies show that loss or gain of genomic materials can activate the oncogenes or inactivate the tumor suppressor genes to predispose cells toward carcinogenesis.

View Article and Find Full Text PDF